PCN42 CABOZANTINIB VERSUS STANDARD-OF-CARE COMPARATORS: A NETWORK META-ANALYSIS OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.239
https://www.valueinhealthjournal.com/article/S1098-3015(19)32617-8/fulltext
Title :
PCN42 CABOZANTINIB VERSUS STANDARD-OF-CARE COMPARATORS: A NETWORK META-ANALYSIS OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32617-8&doi=10.1016/j.jval.2019.09.239
First page :
Section Title :
Open access? :
No
Section Order :
10185